Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)

NCT04114188 is registered in ClinicalTrials.gov with Prof. Dr. Petra Reinke as lead sponsor.

NCT NCT04114188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04114188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)
Lead sponsor
Prof. Dr. Petra Reinke
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2016
Completion date
December 31, 2020
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal transplant rejection